Achillion Pharmaceuticals - Biotech Gold For The Price Of Dirt

|
About: Achillion Pharmaceuticals, Inc. (ACHN), Includes: ALXN
by: Altum Research
This article is exclusive for subscribers.
Altum Research
Long/short equity, Deep Value, biotech, healthcare
Summary

Achillion's book value is roughly $2, while the stock trades in the $2.90s.

The lead asset 4471 is a potent Factor-D inhibitor and relatively orally available.

Failure in bringing its Hep C drug to market with partner Johnson & Johnson destroyed investors' hopes.

The value is very clear, with potential to disrupt multiple rare diseases in the Eculizumab market.

Welcome to Achillion Pharmaceuticals (NASDAQ:ACHN). I've been following the company for a bit, but only after the Johnson & Johnson (NYSE:JNJ) Hep C disaster, so I won't be painting much of